-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $39

Benzinga·08/10/2026 15:10:59
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $39.